These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8085690)

  • 1. Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group.
    Belshe RB; Clements ML; Keefer MC; Graham BS; Corey L; Sposto R; Wescott S; Lawrence D
    Ann Intern Med; 1994 Oct; 121(8):584-9. PubMed ID: 8085690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine.
    Quirk EK; Mogg R; Brown DD; Lally MA; Mehrotra DV; DiNubile MJ; Robertson MN
    Clin Infect Dis; 2008 Dec; 47(12):1593-9. PubMed ID: 18990058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
    Khurana S; Needham J; Mathieson B; Rodriguez-Chavez IR; Catanzaro AT; Bailer RT; Kim J; Polonis V; Cooper DA; Guerin J; Peterson ML; Gurwith M; Nguyen N; Graham BS; Golding H
    J Virol; 2006 Mar; 80(5):2092-9. PubMed ID: 16474117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
    Djomand G; Katzman J; di Tommaso D; Hudgens MG; Counts GW; Koblin BA; Sullivan PS
    Public Health Rep; 2005; 120(5):543-8. PubMed ID: 16224987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
    Dolin R; Graham BS; Greenberg SB; Tacket CO; Belshe RB; Midthun K; Clements ML; Gorse GJ; Horgan BW; Atmar RL
    Ann Intern Med; 1991 Jan; 114(2):119-27. PubMed ID: 1984386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients.
    Ackers ML; Parekh B; Evans TG; Berman P; Phillips S; Allen M; McDougal JS
    J Infect Dis; 2003 Mar; 187(6):879-86. PubMed ID: 12660933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial.
    Sheon AR; Wagner L; McElrath MJ; Keefer MC; Zimmerman E; Israel H; Berger D; Fast P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(5):519-26. PubMed ID: 9859967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Schwartz DH; Graham BS; Matthews TJ; Stablein DM; Frey SE; Belshe RB; Clements ML; Wright PF; Eibl M
    Clin Exp Immunol; 1994 Nov; 98(2):178-84. PubMed ID: 7955519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention.
    Allen M; Lau CY
    Soc Sci Med; 2008 Feb; 66(4):945-51. PubMed ID: 18162272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Domestic AIDS vaccine trials: addressing the potential for social harm to the subjects of human experiments.
    Leider PA
    Calif Law Rev; 2000; 88():1185-232. PubMed ID: 11067733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial-related discrimination in HIV vaccine clinical trials.
    Allen M; Israel H; Rybczyk K; Pugliese MA; Loughran K; Wagner L; Erb S
    AIDS Res Hum Retroviruses; 2001 May; 17(8):667-74. PubMed ID: 11429107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
    Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
    Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya.
    Nyaoke BA; Mutua GN; Sajabi R; Nyasani D; Mureithi MW; Anzala OA
    PLoS One; 2017; 12(9):e0183788. PubMed ID: 28880880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Keefer MC; Belshe RB; Matthews TJ; Forrest BD; Hsieh RH; Koff WC; Hanson CV; Dolin R; Weinhold KJ; Frey SE; Ketter N; Fast PE
    J Infect Dis; 1996 Feb; 173(2):330-9. PubMed ID: 8568293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short communication: Long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers.
    Silbermann B; Tod M; Desaint C; Pialoux G; Petitprez K; Slama L; Poncelet H; Moreau C; Mazarin V; Heshmati F; Salmon-Ceron D; Guillet JG; Launay O
    AIDS Res Hum Retroviruses; 2008 Nov; 24(11):1445-8. PubMed ID: 19000023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of indeterminate western blot tests in healthy adults at low risk for human immunodeficiency virus infection. The NIAID AIDS Vaccine Clinical Trails Network.
    Midthun K; Garrison L; Clements ML; Farzadegan H; Fernie B; Quinn T
    J Infect Dis; 1990 Dec; 162(6):1379-82. PubMed ID: 2230270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.